Scientists are testing an entirely new way to fight heart disease: whether gene editing might offer a one-time fix for high ...

Editas Medicine announces advancements in in vivo CRISPR gene editing, optimizing costs, and reducing workforce while focusing on hematologic diseases. Editas Medicine, Inc. has announced a strategic ...

ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial ...

For most of his 20 years, a New Jersey man knew pain as a daily reality. Now, after a one-time CRISPR gene-editing treatment at Children's Hospital of Philadelphia, Austin Louis says he is finally ...

Precedence Research, a leading strategic research firm, today released a comprehensive overview of the gene therapy and ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other CRISPR stocks.

Urnov is a professor of molecular therapeutics at the University of California, Berkeley, and a director at its Innovative Genomics Institute. In May, news broke of a biomedical first: the on-demand ...

A single infusion of an experimental gene-editing drug appears safe and effective for cutting cholesterol, possibly for life, according to a small early study released Saturday. The study, which ...

DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Prime Medicine, Inc. (NASDAQ:PRME) stands against the other CRISPR stocks.

When KJ Muldoon was born in August 2024 with mutations that led to a missing enzyme he needed to process proteins properly, Ahrens-Nicklas knew she had to act fast. Most with his condition need a ...